Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer

Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer Yanqiao Zhang, Yuanyu Liao, Rui Yang, Bojun Wang, Yuli Ruan, Luying Cui, and 9 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4819905/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 26 Dec, 2024 Read the published version in Oncogene → Version 1 posted 10 You are reading this latest preprint version Abstract Background Inadequate tumor cell-intrinsic interferon response leads to limited efficacy of immune checkpoint blockade (ICB) therapy, such as anti-PD-1. Cholesterol metabolism can sharply regulate anti-tumor immune response. However, the mechanism of cholesterol synthesis affects the tumor cell-intrinsic interferon response in microsatellite instability (MSI) colorectal cancer (CRC) remains unclear. Method Small interfering RNA(siRNA) libraries and GSEA enrichment analysis are employed to screen out the key molecular which affects the tumor cell-intrinsic interferon response in MSI CRC. Mass cytometry and multiple immunofluorescence (mIF) for detecting changes in tumor micro-environment. The confocal immunofluorescence (IF), truncated protein construction, and co-immunoprecipitation (co-IP) were utilized to investigate the mechanism. The efficacy of immunotherapy were assessed in subcutaneous transplantation tumor models and human peripheral blood mononuclear cells-patient derived xenografts(hPBMC-PDX) models. Results Using the siRNA library and GSEA analysis, we revealed that mevalonate kinase (MVK) notably impairs the tumor cell-intrinsic interferon response in MSI CRC cells. After MVK gene knockout, the levels of Th1 type chemokines (CXCL9 and CXCL10) and the abundance of CD8 + T cells were increased in tumor, and tumor growth was significantly slowed in mice with intact immune systems. Mechanistically, MVK interacts with the transcriptional activation domain (TAD) of signal transducer and activator of transcription 1 (STAT1), a key transcription factor in the interferon response. This interaction leads to reduced nuclear translocation of STAT1, ultimately impacting interferon reactivity. In the analysis of the hPBMC-PDX model and the MSI CRC clinical cohort, we observed that a low level of MVK in tumors is associated with a significant efficacy of anti-PD-1 therapy. Conclusion MVK is the crucial medium in the cholesterol metabolism to inhibit the tumor cell-intrinsic interferon response of tumor cells. Moreover, targeting MVK is promising to increase the efficacy of ICB therapy by increasing the interferon response in MSI CRC. Biological sciences/Cancer/Oncogenes Biological sciences/Cancer/Tumour immunology/Immunosurveillance Colorectal cancer Tumor cell-intrinsic interferon response Mevalonate kinase STAT1 phosphorylation Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Introduction Immune checkpoint blockade (ICB) by the anti-PD-1 monoclonal antibody or anti-CTLA-4 monoclonal antibody, has been approved for treating microsatellite instability colorectal cancer (MSI CRC) [ 1 ] . Clinical trials of KEYNOTE-177 and CHECKMATE-142 indicate that half of MSI CRC patients experience limited efficacy from single or dual immunotherapy regimens [ 2 – 3 ] . Tumor cell-intrinsic interferon response significantly affects anti-tumor immune resistance and the efficacy of immunotherapy [ 4 – 7 ] . Within the tumor microenvironment, activated T cells and NK cells release IFN-γ, triggering JAK1 and STAT1 phosphorylation and enhancing the transcription of Th1 type cytokines (CXCL9, CXCL10, and CXCL11) and antigen-presenting molecules. This activation pathway can recruit anti-tumor immune cells and bolstering cytotoxic activity [ 8 – 9 ] . Absence of IFN-γ receptors or mutations in JAK1/STAT1 in tumor cells can suppress T cell-mediated immune responses and lead to immune evasion [ 10 ] . Furthermore, clinical cohorts of melanoma, non-small cell lung cancer, and MSI CRC all revealed that JAK1 and B2M gene mutations are correlated with the efficacy of ICB therapy [ 11 – 14 ] . Abnormally activated cholesterol synthesis is a metabolic hallmark in colorectal cancer and a crucial mechanism of promoting tumor immune evasion [ 15 – 16 ] . However, the potential crosstalk between the cholesterol synthesis and tumor cell-intrinsic interferon response remains unclear. Mevalonate pathway is the main source of cholesterol synthesis in vivo. Besides the metabolic synthesis functions, several enzymes of mevalonate pathway have been proved affect the conduction of signaling pathways. 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) promotes MYC phosphorylation by stabilizing the activity of RacGTPase, thereby promoting the development of hepatocellular carcinoma [ 17 ] . Cytochrome P450 family 27 subfamily A member 1 (CYP27A1) overexpresses in various cancers and produces 27-hydroxycholesterol (27HC), 27HC has been demonstrated that can induce AKT activation and the secretion of IL-6, vascular endothelialgrowth factor (VEGF), resulting in CRC development [ 18 ] . In addition, the knockdown of sterol regulatory element binding transcription factor (SREBP) could suppress tumor growth in xenograft models of colon cancer and downregulate the expression of genes associated with cell stem [ 19 ] . These findings indicate that cholesterol metabolizing enzymes may impact interferon reactivity through non-biochemical mechanisms. In this study, we identified MVK was the key medium in the crosstalk between cholesterol metabolism and the tumor cell-intrinsic interferon response. We sought to demonstrate the underlying mechanism by which MVK affects interferon reactivity in both vitro and vivo. Finally, the expression level of MVK and the efficacy of ICB therapy were demonstrated in animal models and clinical cohorts. Our current study is promising to explain the limited effectiveness of ICB therapy in some MSI CRC patients from the perspective of abnormal cholesterol metabolism affecting interferon reactivity. This is expected to provide theoretical support for the development of targeted MVK-sensitizing ICB therapies. Material and Methods Cell culture, Reagents, and antibodies Human cell lines (CCD-841CoN,RKO,HCT15,HT29,HCT116,SW48,SW620,SW480 SW948,DLD1) and mouse cell lines(MC38,CT26) were acquired from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China).These cell lines were routinely authenticated by quality examinations of morphology and short tandem repeat (STR) markers by the supplier.All cells were mycoplasma-free and cultured in RPMI 1640 medium (Gibco, USA) or DMEM medium (Gibco, USA), containing 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin (Gibco United States). All cells were kept at 37°C in a humidified incubator supplied with 5% CO2. The CRISPR/Cas9 technology were using to create CT26 Msh2 -knockout cells. Plasmids containing GFP, Cas9 and puromycin resistance markers, and single guide RNAs (sgRNA) targeting exon 2 of mouse MSH2 (the sequences are sg1:5’-CCTGGGTCTTGAACACCTCG-3’; sg2:5’-GGGCTTCGTGCGCTTCTTTG-3’) were cotransfected into CT26 cells. The transfected cells were treated with puromycin (2 µg/ml) and selected by FACS. Cell clones were enriched in 96-wells plates. The qRT-PCR and western blot analysis were used to verify the expression of MSH2 . The antibodies involved are listed in Supplementary Table S1 ,and drugs utilised in this work include Atorvastatin (S5715, Selleck), IFN-γ (I17001/I4777, Sigma), Anti-mouseCD8α-inVivo(A2102, Selleck), Anti-mousePD1-inVivo(A2122, Selleck). Patients and Clinical Specimens The colorectal tumours and paired normal tissues were collected from 68 MSIH-H CRC patients who underwent radical resection in the Department of Colorectal Surgery, Harbin Medical University Affiliated Cancer Hospital. The patients detailed statistics are provided in Table S5 . Serum samples were obtained from 3 patients of CRC. Informed written consents were obtained from all subjects. None of the patients in this study had undergone prior surgeries or been taking any medication. The research protocol involving human conforms to the principles of the Helsinki Declaration and was approved by the Clinical Research Ethics Committee of the Cancer Hospital affiliated with Harbin Medical University.(Approval number:KY2023-57) Plasmid and truncated protein The full-length myc/flag-tagged human MVK/STAT1 cDNA were obtained from General Biology(Anhui, China). The myc/flag-tagged mouse Mvk cDNA are synthesized in laboratory based on the transcripts from NCBI database, using the pCDH-EF1-MCS-CMV-copGFP-T2A-Puro vector General Biology(Anhui, China).Sequences of the transcriptss used for plasmid construction are listed in Supplementary Table S4 . Using the plasmid of wildtype human STAT1 as the template, truncate five structural domains separately(TAD:between amino acids from 683 to 750)(SH2:between amino acids from 481 to 683)(DBD:between amino acids from 317 to 481)(CCD:between amino acids from 138 to 317)(NT:between amino acids from 1 to 138). All sequences of truncated proteins are listed in Supplementary Table S4 . Additionally, the siRNAs of human MVK, MVD, FDFT1, ACAT2, GGPS1, FDPS, PMVK, HMGCR, HMGCS1 and IDI1 were obtained from General Biology(Anhui,China). (Supplementary Table S2 -siRNA sequences). Lentivirus transduction and CRISPR‒Cas9 gene editing We used pCDH-EF1-MCS-CMV-copGFP-T2A-Puro lentiviral vectors obtained from General Biology(Anhui,China) to clone MVK sequences. The lentivirus were subsequently used to package the vectors and infected cells for six hours. The MVK overexpressing cells were selected by medium containing puromycin (Sigma). The CRISPR/Cas9 technology were using to create MVK -knockout cells. Plasmids containing GFP, Cas9 and puromycin resistance markers, and single guide RNAs (sgRNA) targeting exon 2 of mouse MVK were cotransfected into cells for 24h. The transfected cells were treated with puromycin (2 µg/ml) and selected by FACS. Cell clones were enriched in 96-wells plates. The qRT-PCR and western blot analysis were used to verify the expression of MVK after 14 − 20 days.(Supplementary Table S4 -sgRNA sequences). Co-immunoprecipitation For co-immunoprecipitation (Co-IP), the 1mL lysis buffer were used to treat 10 6 cells on ice for 20 min and centrifuged at 12,000 rpm for 15 min at 4℃. The supernatant was incubated with 50µL anti DYKDDDDK magnetic agarose suspension (A36798, ThermoFisher) for 30 minutes at room temperature, followed by collecting magnetic agarose with Magnetic frame.After washing by lysis buffer, magnetic agarose were boiled with 5x loading buffer for 10 min followed by western blotting analyse. The plasmid of flag-tagged STAT1 and flag-tagged truncations, were transiently transfected with transfection reagent for 48 h. Cells were lysed bt radioimmunoprecipitation assay (RIPA) buffer in the presence of complete protease inhibitors and used anti DYKDDDDK magnetic agarose for immunoprecipitation. Multi-color IHC (mIHC) Formalin-fixed paraffin-embedded tissue (FFPE) sections from subcutaneous transplant tumor tissue were cut in 4µm serial sections. Conduct antigen retrieval using the immunohistochemical protocol until the primary antibodies were incubated (Primary antibodies included CD3 and CD8a). Subsequently, multi-color IHC was performed using the five-color multiplex fluorescent immunohistochemical staining kit (abs50013, ABSIN). The position of the primary antibodies binding specific antigen were paired to TSA fluorophore from the kit. All fluorophores and DAPI were prepared according to manufacturer guidelines. For multiple fluorescent staining, sections were processed starting from the antigen retrieval step to remove binding antibodies, and then they were incubated with another primary antibody. This was repeated until all antigens were stained. Finally, counterstaining was performed with DAPI and anti-fluorescence quenching blocker was added dropwise. Images were captured using an Olympus BX53 microscope under suitable laser excitation conditions. Mass Cytometry Stain 6 to 11 million Percoll-enriched cells with 0.5mM cisplatin in 1mL PBS (without Ca2 + and Mg2+) at room temperature for 2 minutes. Add 2mL of cell staining buffer (Fluidigm, catalog number 201068) to halt the reaction, and centrifuge the mixture at 500 × g for 5 minutes. Following Fc blockade (BioLegend, Cat # 422302), the cells were incubated with a cocktail of metal-labeled antibodies, including 41 types (Supplementary Table S1 .), at room temperature for 30 minutes. After washing with the cell staining buffer, the cells were incubated with 125mM Intercator Ir (Fluidigm, Cat # 201192A) in fixed and osmotic buffer (Fluidigm, Cat # 201067) at room temperature for 1 hour. Subsequently, wash the cells twice with Maxpar water (Fluidigm, Cat # 201069), mix with EqBeads (Fluidigm, Cat # 201078), and analyze on a CyTOF Helios machine. Refer to Supplementary Table S1 for the detailed staining protocol. Construction of hPBMC-PDX model and therapeutic experiments in vivo Immediately following surgical removal, fresh colorectal cancer tumor samples were collected and transported in cold complete culture medium. The tissue was then sectioned into 2-3mm pieces and implanted into NYG mice from Charles River (Beijing, China), which are immunodeficient due to knockout mutations in Prkdc and Il2rg genes. The growth of the xenografts was monitored twice weekly using calipers, and subsequent passaging commenced once the tumor volume reached approximately 0.1 cm 3 .Upon reaching the third passage, inject human PBMCs (approximately 5 x 10 6 ) into NYG mice, to create a humanized PBMC-PDX model. Suspend the human PBMCs at a density of 4 x 10 6 cells per 0.1 ml in sterile phosphate-buffered saline and inject them intraperitoneally with a 1-cc tuberculin syringe.NYG mice can receive donor PBMCs that match or do not match the PDX implanted in their bodies. Donor blood samples do not require HLA typing. Approximately 2 weeks after injection, perform flow cytometry analysis to assess the human cells in the mice. Mice with a human CD45 + cell percentage of > 1% are included in the experimental group. Monitor the health status of mice daily following human cell implantation. Based on the growth rate of huPBMC-PDX, mice were randomly added to treatment group and control group when the size of tumour reached 0.1 cm 3 approximately. The hPBMC-PDX model was raised in the pathogen-free environment. Treatment groups received the following: Anti mouse PD-1 monoclonal antibody in vivo (0.2 mg/mice, twice a week, i.p.) or PBS. Each experimental group includes 3 mice with Unilateral implanted tumors. Record tumor growth every 3 to 4 days and calculate tumor volume using the formula V=(length x width 2 ). If the tumor's size exceeds 1.5 centimeters in any dimension, the mouse will be humanely euthanized.(Approval number:KY2023-57) Subcutaneous transplantation tumor model in mice and therapeutic experiments Six-week-old female C57BL/6,BALB/c,and BALB/c-nude mice obtained form Charles River(Beijing,China) were subcutaneously injected with 1 × 10 6 cells into the right flank.Upon tumour formation, treatment was initiated with Anti mouse PD-1 monoclonal antibody in vivo (0.2 mg/mice, twice a week, i.p.); Atorvastatin (0.2 mg/mice daily, p.o.); Anti mouse PD-1 monoclonal antibody in vivo (0.2 mg/mice, twice a week, i.p.) + Atorvastatin (0.2 mg/mice daily, p.o.).Tumour dimensions were consistently monitored every other day using Vernier callipers, and the volume was calculated using the formula: V = [length × (width) 2 ]/2. Mice were euthanised if the tumour lengths exceeded 1.5 cm in any direction. (Approval number:KY2023-57) Statistical analysis The mean ± standard deviation denotes the presentation of quantitative data. GraphPad Prism (RRID: SCR_002798) was employed to assess statistical significance using a two-tailed unpaired Student's t-test. Statistical significance is defined as p-values less than 0.05: p < 0.05, p < 0.01, and p < 0.001. At least three independent biological replicates were used in each experiment. The R value is determined by Spearman correlation analysis. Results 1.MVK impairs the tumor cell-intrinsic interferon response in MSI CRC To identify the specific mediators involved in cholesterol synthesis and the tumor cell-intrinsic interferon response, we conducted a screening of the key enzymes within the mevalonate pathway, using both siRNA library and GSEA (Fig. 1A, Sup1A). We assessed the gene expression levels of these enzymes and their enrichment with the interferon signaling pathway from the TCGA-CRC cohort, identifying the MVK having the highest enrichment score (Fig. 1B). Additionally, we employed siRNA to interfere with the expression of the enzymes in the MSI CRC cell line HCT116 (Sup1B), and assessed alterations in the expression levels of Th1 type cytokines (CXCL9 and CXCL10) using qRT-PCR and flow cytometry. The findings revealed that, disrupting MVK expression led to the most pronounced elevation in CXCL9 and CXCL10 levels (Fig. 1C, 1D). Subsequently, we gathered paraffin-embedded tumor samples of 68 MSI CRC patients, along with adjacent normal specimens, and discovered that within MSI CRC tumor tissues, higher MVK expression levels correlated with lower levels of CXCL9 and CXCL10, and reduced infiltration of CD8 + T cells (Fig. 1E). Analysis of transcriptome data from the TCGA-CRC database further validated these findings (Sup1C). We assessed the basal expression of MVK in various human MSI CRC cell lines and three enterocyte lines (Sup1E). We selected two cell lines with high basal MVK expression along with two mouse colorectal cancer cell lines, and used CRISPR-Cas9 to knock out the MVK gene (Sup1H). In these four MVK-knockout cell lines, we observed a significant increase in the transcription levels of CXCL9 and CXCL10 following IFN-γ stimulation, compared to the MVK wild-type (Fig. 1F). Regarding the basal expression of MVK, the results were consistent with the variations noted in the TCGA-CRC database (Sup1D), the WB and IHC analysis also revealed that MVK expression was significantly higher in colorectal cancer tissues than in normal tissues (Sup1F-G). 2.MVK influences the growth of MSI CRC via the tumor cell-intrinsic interferon response To verify the potential influence of MVK on the progression of CRC cells, we compared the growth and migration of CRC cell lines in vitro with CCK-8 and cell migration assay. The results indicate that no differences in proliferation and migration of these MSI CRC cells following MVK gene knockout (Sup2A-H). In vivo experiments, we established mouse subcutaneous transplant tumor models (Fig. 2A, H) using the MC38- Mvk WT/KO and CT26 Msh2 −/− - Mvk WT/KO cell lines. We observed that the tumors generated by the Mvk KO cell lines were significantly suppressed in both growth rate and tumor weight compared to the control cell lines ( Mvk WT ) (Fig. 2B-D, Fig. 2I-K). To reconfirm the impact of MVK on the tumor cell-intrinsic interferon response in vivo, the IHC revealed a significant increase in the number of CD8 + T cells and expression of CXCL9 and CXCL10 within all subcutaneous transplant tumors derived from the Mvk KO cell lines(Fig. 2E-G,Fig. 2L-N). The qRT-PCR experiments demonstrate that the transcription level of the CXCL9 and CXCL10 in subcutaneous transplanted tumors is significantly elevated as a result of MVK knockout (Sup2I-J). However, when we injected the MC38- Mvk WT/KO cell lines into BALB/c-nude mice which lacking intact immune system (Fig. 2O), we observed no differences in tumor growth among these immunodeficient mice (Fig. 2P-R), indicating that the inhibition of MVK on MSI CRC growth is dependent on the intact immune system. 3.MVK significantly modifies the cytotoxic T lymphocytes (CTL) in MSI CRC tumor To investigate the specific impact of MVK on MSI CRC, we conducted mass cytometry analysis (Fig. 3A-B) on MC38- Mvk WT/KO subcutaneous transplanted tumors from C57BL/6 mice. These tumor-infiltrating lymphocytes were segmented into distinct subgroups based on the cell surface markers (Fig. 3A-B). Within the Mvk KO group, we observed a significant elevation in the number of T cell subset, particularly CD8 + T cells (Fig. 3C). Additionally, these T cells displayed a notable upregulation in the expression of effector molecules, such as IFN-γ and GZMB (Fig. 3D). We also stained the subcutaneous transplanted tumors from each group and detected a marked increase in CD8 + T cells within the MVK knockout group via flow cytometry (Sup3A). Concurrently, mIF revealed that, compared to MVK wild-type tumors, the MVK knockout group exhibited a substantial rise in the numbers of CD3 and CD8 cells within the tumor center, though these differences were not apparent at the tumor margins (Fig. 3E). To further validate the role of MVK in influencing tumor growth via CD8 + T cells, we administered anti-CD8a antibodies to the Mvk WT/KO group, effectively depleting CD8 + T cells (Sup3E). Our results demonstrate that, following the depletion of CD8 + T cells, the subcutaneous transplanted tumors in the MVK knockout group resumed their growth (Fig. 3F-I). To exclude the interference caused by potential changes in tumor immunogenicity, we employed immunofluorescence to assess γ-H2AX expression and whole exome sequencing to monitor alterations in genomic mutation levels in both Mvk WT and Mvk KO cell lines. These experiments revealed no significant differences in DNA damage or exon mutation rates in cells with MVK knocked out (Sup3B-D). 4. MVK impairs the phosphorylation of STAT1 within the interferon response We further explored the mechanism of MVK regulating the interferon response. Initially, we transfected the Flag-MVK plasmid into the human cell line RKO and the mouse cell line MC38, and verified the interactions among key proteins in the interferon signaling pathway using CO-IP experiments (Sup4A). The WB revealed an interaction between MVK and STAT1 protein (Fig. 4A). Subsequently, when we transfected the Flag-STAT1 plasmid for CO-IP experiments, we have observed the same result (Fig. 4B). Additionally, using IF we demonstrated the co-localization of STAT1 and MVK proteins in cytoplasm (Fig. 4C). STAT1 comprises five distinct functional domains [ 20 ] . To clarify how MVK influences STAT1's function, we reconstructed five truncated forms of STAT1 (Fig. 4D). The CO-IP experiments revealed that MVK binds to the TAD region of STAT1. Using the AlphaFold2 website to predict protein-protein interactions, we discovered a high level of interaction between MVK and the TAD region of STAT1(Sup4B). We transfected the Flag-STAT1 plasmid into both MVK knockout and wild-type of RKO and MC38. Co-IP experiments revealed a significant increase in the binding levels of STAT1 and JAK1 proteins in the MVK knockout strains (Fig. 4E). Following stimulation with IFN-γ, a notable elevation in the phosphorylation levels of STAT1 was observed in the MVK knockout strains (Fig. 4F). Additionally, through Lucifer and IF assays, we observed that the nuclear accumulation of pSTAT1 was significantly higher in MVK-knockout cells compared to the control group after IFN-γ stimulation (Sup4C- D). Intriguingly, after adding atorvastatin, a clinically prescribed cholesterol-suppressing drug, to the culture medium for colorectal cancer cells, we observed a dose-dependent reduction in MVK expression levels. And subsequently led to heightened levels of STAT1 and JAK1 protein binding (Sup4E). 5.MVK replenishment in MVK-deficient tumor cells re-suppresses the interferon response To verified the function of MVK impacting interferon response, we leveraging the Mvk KO cell lines established in Fig. 1 to generate stable MVK over-expressing lines through lentivirus. We observed that rescuing MVK significantly reduced the phosphorylation levels in cells stimulated with IFN-γ, without affecting the baseline expression of STAT1 (Fig. 5A). To further confirm the tumor cell-intrinsic interferon response in MSI CRC, we utilized that rescuing MVK significantly attenuated the upregulation of CXCL9 and CXCL10 RNA levels following interferon stimulation (Fig. 5B). In vivo experiments, we observed that subcutaneous transplanted tumors with the wild-type MVK experienced accelerated growth following MVK overexpression. Subcutaneous transplanted tumors with MVK knockdown resumed growth following restoration of MVK expression (Fig. 5C-J). We then performed mIF experiments on the subcutaneous transplanted tumors. Within the tumor microenvironment, the restoration of MVK expression led to a significant reduction in the numbers of CD3 and CD8 + T cells (Fig. 5K-L). The IHC experiments have also demonstrated similar alterations in the level of CXCL9, CXCL10 and CD8 + T, potentially contributing to the resumed tumor growth in mice (Sup5A-D). 6.Suppression of MVK improves the effectiveness of immunotherapy in MSI CRC We postulate whether inhibiting MVK expression might enhance T cell infiltration and improve the effectiveness of ICB immunotherapy. For this purpose, we established subcutaneous transplant tumor models with Mvk WT/KO cells in C57BL/6 and BALB/C mice, and treated them with anti-PD-1 monoclonal antibodies (Fig. 6A, Sup6A). The results revealed that in these mouse tumor models, the MVK knockout group demonstrated significantly greater anti-PD-1 therapeutic efficacy compared to the wild-type group (Fig. 6B-C and Sup6B-C). We further analyzed tumor tissues using IHC and flow cytometry, and consistent with our prior findings, the MVK knockout group displayed increased levels of Th1 chemokines and CTL cells, which contribute to the superior immune therapeutic response (Fig. 6D-E and Sup6D-E). Considering the inhibitory effect of statins on MVK (Sup4E), we unexpectedly discovered that atorvastatin suppresses the expression of MVK. Consequently, we conducted experiments in vivo to investigate the sensitizing effect of atorvastatin on ICB efficacy (Fig. 6F and Sup6F), revealing that, while atorvastatin lacks intrinsic antitumoral activity, it significantly enhances the therapeutic efficacy of anti-PD-1 monoclonal antibodies (Fig. 6G-J and Sup6G-J). 7.The expression of MVK influences the immunotherapy response in MSI CRC patients Based on the experimental results above, we constructed a hPBMC-PDX model with human immune system to further assess the impact of MVK on the immunotherapy for MSI CRC patients. The hPBMC-PDX model was randomly assigned to either the treatment or control group and treated with PD-1 monoclonal antibody (Fig. 7A). The results demonstrated that the hPBMC-PDX models with low MVK expression exhibited superior immunotherapy efficacy compared to those with high MVK expression (Fig. 7B-D). Analysis of the tumor micro-environment revealed a significant increase in the proportion of CLT cells and Th1 type chemokines in the tumor tissues of mice with low MVK expression levels (Fig. 7E-F). Furthermore, our follow-up observations on the immunotherapy efficacy in the three parental patients. The imaging results indicate that compared with patients with high MVK expression, patients with low MVK expression have a more significant reduction in liver metastasis and exhibit better treatment responsiveness after anti-PD-1 treatment(Fig. 7G). To further assess the clinical relevance, we gathered imaging examination and paraffin-embedded tumor tissue samples from 14 MSI CRC patients who undergone immunotherapy at our center. The therapeutic efficacy was assessed using CT scans, and patients were categorized based on their MVK immunohistochemical scores (Fig. 7F). Our findings revealed that patients with low MVK expression demonstrated significantly greater sensitivity to immunotherapy compared to those with high MVK expression, with notably elevated proportions of PR and CR patients (Fig. 7H-I). Discussion Tumor cells influences the anti-tumor immune response through abnormal cholesterol metabolism. For instance, cholesterol induces the expression of molecules like LAG-3 and PD-1 on CD8 + T cells, leading to T cell exhaustion and subsequently diminishing immunotherapy outcomes in melanoma [ 21 ] . In thymus, cholesterol specifically downregulates T cell signaling and impedes T cell maturation through a complex with TCR-CD3 [ 22 ] . Besides the direct impact of cholesterol on cancer immunotherapy, numerous key enzymes within mevalonate pathway are also implicated in crosstalk with several signaling pathways. Knockdown of the geranylgeranyl diphosphate synthase 1 (GGPS1) gene markedly influences the membrane localization and activity of KRAS in CRC cells [ 23 ] . HMGCS1 activates the pyroptosis pathway in ovarian cancer, thereby enhancing the effectiveness of immunotherapy [ 24 ] . Sterol regulatory element binding transcription factor 2 (SREBF2) enhances liver metastasis of rectal cancer via the activation of the PI3K-AKT-mTOR signaling pathway [ 25 ] . Resistance to ICB therapy is partly due to the inadequate intrinsic interferon response in tumor cells [ 26 – 29 ] . Exome sequencing in melanoma reveals that patients resistant to ICB frequently display mutations in the JAK1, JAK2, and β-2 microglobulin(B2M) genes. The mutated JAK1 in these patients fails to upregulate the expression of ISG genes following IFN-γ stimulation [ 30 – 31 ] . Furthermore, reduced expression levels of genes like IFNGR1, JAK1, and STAT1 can significantly impact the survival of melanoma patients [ 7 ] . Liao et al. also discovered that USP4 disrupts the interferon response in colorectal cancer cells, resulting in ineffective immunotherapy [ 32 ] . Therefore, an inadequate intrinsic interferon response in tumor cells represents a limiting factor for ICB treatment. In our research, employing the small interfering RNA library, we identified MVK, a key enzyme in the mevalonate pathway, significantly impacting the intrinsic interferon response of tumor cells. MVK has been demonstrated to be highly expressed in gastric cancer and prostate cancer, and significantly impacting patients' 5-year overall survival [ 33 – 34 ] . In this study, we discovered that MVK expression is markedly elevated in CRC, yet its effect does not depend on influencing tumor cell proliferation or invasion. The mouse subcutaneous tumor models also indicate that MVK primarily affects MSI CRC via the intact immune system. Mechanistically, MVK knockout markedly enhanced the abundance of CD8 + T cells. Prior research has indicated that the increase of CD8 + T cells within the tumor micro-environment correlates with the generation of neoantigens, and both DNA damage and exon mutations in tumor cells have the potential to elevate neoantigen levels [ 35 – 36 ] . We also clariid that there are no differences in neoantigen levels. We found that MVK binds to the TAD of STAT1, disrupting the phosphorylation cascade between JAK1 and STAT1. This interaction subsequently diminishes the nuclear translocation of STAT1. Ultimately, this impaired the interferon response within tumor cells, rendering the ICB treatment ineffective. Furthermore, we observed a significant correlation between MVK expression levels and the effectiveness of immunotherapy for MSI CRC in clinical cohorts. As the inhibitor of mevalonate pathway, statins inhibit tumor cell proliferation, promote tumor cell apoptosis, modulate inflammation, endothelial function, and angiogenesis [ 37 – 38 ] . Mechanistically, when statins inhibit the mevalonate pathway, they concurrently decrease the production of intermediates such as isoprene, farnesyl pyrophosphate, and geranyl pyrophosphate. These products are closely linked to the activation of small G proteins like Ras and Rho [ 39 – 40 ] . In CRC, using statins either alone or in conjunction with celecoxib, has been shown to decrease polyp formation in genetically susceptible mice with multiple intestinal neoplasia(Min) mouse [ 41 – 42 ] . Leveraging the pleiotropic properties of statins, our study discovered that these drugs can suppress the expression of the MVK. We proposed the scientific hypothesis for combined statin and immunotherapy, which was further validated through enhanced therapeutic efficacy observed in mouse subcutaneous tumor model. Nonetheless, this study mainly focuses on atorvastatin, while other statin drugs have not been included. In addition, the precise mechanism by which statins inhibit MVK expression also worth further exploration. To clarify the mechanism of cholesterol in modulating the interferon response of MSI CRC cells. W e identified the MVK, a key enzyme in cholesterol synthesis, disrupts the interferon response of colorectal cancer cells via its non-biochemical function. This crosstalk ultimately diminishes the effectiveness of ICB therapy. Consequently, this research offers the novel targets to enhance the efficacy of immunotherapy for MSI CRC, also positioning MVK as a potential biomarker for predicting the immunotherapeutic prognosis in MSI CRC. Declarations These authors contributed equally Conflicts of Interest The authors declare they have no conflicts of interest Acknowledgements: We express our heartfelt gratitude to Professor Shuijie Li of Harbin Medical University for his guidance and invaluable advice on this work. Funding for this work was provided by grants from the National Natural Science Foundation of China (nos. U22A20330, 82173233, 82373372, and 82102858), the Key Project of Research and Development Plan in Heilongjiang Province (no. 2022ZX06C01, JD2023SJ40), the Natural Science Funding of Heilongjiang (no. YQ2022H017) and Haiyan Research Fund of Harbin Medical University Cancer Hospital (JJJQ2024-02). References Asaoka Y, Ijichi H, Koike K. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;373(20):1979. Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659–670. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022;40(2):161–170. Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity. 2016;44(6):1255–1269. Vesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022;40:45–74. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397–404.e9. Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, et al. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8:15440. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40–47. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2017;7(2):188–201. Thompson JC, Davis C, Deshpande C, Hwang WT, Jeffries S, Huang A, et al. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J Immunother Cancer. 2020;8(2):e000974. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819–829. Bortolomeazzi M, Keddar MR, Montorsi L, Acha-Sagredo A, Benedetti L, Temelkovski D, et al. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. Gastroenterology. 2021;161(4):1179–1193. Zhang C, Li D, Xiao B, Zhou C, Jiang W, Tang J, et al. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy. J Immunother. 2022;45(4):187–193. Jun SY, Brown AJ, Chua NK, Yoon JY, Lee JJ, Yang JO, et al. Reduction of Squalene Epoxidase by Cholesterol Accumulation Accelerates Colorectal Cancer Progression and Metastasis. Gastroenterology. 2021;160(4):1194–1207.e28. Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, et al. Cholesterol Induces CD8 + T Cell Exhaustion in the Tumor Microenvironment. Cell Metab. 2019;30(1):143–156.e5. Hu J, Liu N, Song D, Steer CJ, Zheng G, Song G. A positive feedback between cholesterol synthesis and the pentose phosphate pathway rather than glycolysis promotes hepatocellular carcinoma. Oncogene. 2023;42(39):2892–2904. Xiao W, Hu C, Ni Y, Wang J, Jiao K, Zhou M, et al. 27-Hydroxycholesterol activates the GSK-3β/β-catenin signaling pathway resulting in intestinal fibrosis by inducing oxidative stress: effect of dietary interventions. Inflamm Res. 2024;73(2):289–304. Wen YA, Xiong X, Zaytseva YY, Napier DL, Vallee E, Li AT, et al. Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer. Cell Death Dis. 2018;9(3):265. Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell. 2022;185(21):3857–3876. Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, et al. Cholesterol Induces CD8 + T Cell Exhaustion in the Tumor Microenvironment. Cell Metab. 2019;30(1):143–156.e5. Wang F, Beck-García K, Zorzin C, Schamel WW, Davis MM. Inhibition of T cell receptor signaling by cholesterol sulfate, a naturally occurring derivative of membrane cholesterol. Nat Immunol. 2016;17(7):844–850. Jia WJ, Jiang S, Tang QL, Shen D, Xue B, Ning W, et al. Geranylgeranyl Diphosphate Synthase Modulates Fetal Lung Branching Morphogenesis Possibly through Controlling K-Ras Prenylation. Am J Pathol. 2016;186(6):1454–1465. Zhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell. 2023;41(4):740–756.e10. Zhang KL, Zhu WW, Wang SH, Gao C, Pan JJ, Du ZG, et al. Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics. 2021;11(13):6560–6572. Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS One. 2017;12(11):e0176181. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. Du W, Hua F, Li X, Zhang J, Li S, Wang W, et al. Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. Cancer Discov. 2021;11(7):1826–1843. Middha S, Yaeger R, Shia J, Stadler ZK, King S, Guercio S, et al. Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precis Oncol. 2019;3:PO.18.00321. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819–829. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez, et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017;19(6):1189–1201. Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 2022;13(1):5644. Pisanti S, Picardi P, Ciaglia E, D'Alessandro A, Bifulco M. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res. 2014;88:84–98. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40(9–10):575–584. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016;17(4):1206. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319(5868):1352–1355. Ahmadi M, Amiri S, Pecic S, Machaj F, Rosik J, Łos MJ, et al. Pleiotropic effects of statins: A focus on cancer. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165968. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5(12):930–942. Weissenrieder JS, Reilly JE, Neighbors JD, Hohl RJ. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models. Prostate. 2019;79(1):21–30. Chang WC, Cheng WC, Cheng BH, Chen L, Ju LJ, Ou YJ, et al. Mitochondrial Acetyl-CoA Synthetase 3 is Biosignature of Gastric Cancer Progression. Cancer Med. 2018;7(4):1240–1252. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV, et al Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006;66(14):7370–7377. Teraoka N, Mutoh M, Takasu S, Ueno T, Yamamoto M, Sugimura T, et al. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res (Phila). 2011;4(3):445–453. Additional Declarations There is NO conflict of interest to disclose. Supplementary Files Sup1.pdf Sup2.pdf Sup3.pdf Sup4.pdf Sup5.pdf Sup6.pdf Table1.XXXXXXXXXXXX.docx Table2.siRNAXXXXXX.docx Table3.XXXXXXpCRXXXXXXXXXXXX.docx Table4.XXXXXXXXXXXXXXXXXXXXXXXXXXX.docx Table5.XXXXXXXXXXXX.docx Table6.XXXXXXXXXXXX.docx Cite Share Download PDF Status: Published Journal Publication published 26 Dec, 2024 Read the published version in Oncogene → Version 1 posted Editorial decision: revise 18 Sep, 2024 Review # 2 received at journal 10 Sep, 2024 Review # 1 received at journal 01 Sep, 2024 Reviewer # 2 agreed at journal 26 Aug, 2024 Reviewer # 1 agreed at journal 16 Aug, 2024 Reviewers invited by journal 12 Aug, 2024 Submission checks completed at journal 31 Jul, 2024 First submitted to journal 30 Jul, 2024 Unknown event 29 Jul, 2024 Editor assigned by journal 29 Jul, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4819905","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":339250819,"identity":"a2de4fab-d471-45d3-8573-dd9954ebc175","order_by":0,"name":"Yanqiao Zhang","email":"data:image/png;base64,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","orcid":"","institution":"","correspondingAuthor":true,"prefix":"","firstName":"Yanqiao","middleName":"","lastName":"Zhang","suffix":""},{"id":339250820,"identity":"7b628a5f-edd3-4d98-b867-c4bdc0a532a4","order_by":1,"name":"Yuanyu Liao","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Yuanyu","middleName":"","lastName":"Liao","suffix":""},{"id":339250821,"identity":"9da2c540-dce9-480d-bb58-75fbe370557b","order_by":2,"name":"Rui Yang","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Rui","middleName":"","lastName":"Yang","suffix":""},{"id":339250822,"identity":"3020e193-56d7-4495-9e48-7ad0d6b8ee43","order_by":3,"name":"Bojun Wang","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Bojun","middleName":"","lastName":"Wang","suffix":""},{"id":339250823,"identity":"e63cf89f-ff16-47c9-9509-69190ec01174","order_by":4,"name":"Yuli Ruan","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Yuli","middleName":"","lastName":"Ruan","suffix":""},{"id":339250824,"identity":"a26736e5-ad3f-47b2-a931-a52482f08eab","order_by":5,"name":"Luying Cui","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Luying","middleName":"","lastName":"Cui","suffix":""},{"id":339250825,"identity":"73c81db8-81d2-44b6-84fc-837dbfd05ee7","order_by":6,"name":"Jiani Yang","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Jiani","middleName":"","lastName":"Yang","suffix":""},{"id":339250826,"identity":"a3c44eac-3f51-49af-8587-42a04a114c3f","order_by":7,"name":"Xuefan Yu","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Xuefan","middleName":"","lastName":"Yu","suffix":""},{"id":339250827,"identity":"02cbde90-1c66-41f6-b430-efd9b23ec00c","order_by":8,"name":"Shuling Han","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Shuling","middleName":"","lastName":"Han","suffix":""},{"id":339250828,"identity":"4c74772a-46c4-4497-9795-e44e5d81386a","order_by":9,"name":"Yuanfei Yao","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Yuanfei","middleName":"","lastName":"Yao","suffix":""},{"id":339250829,"identity":"f34ba1c5-eaef-4e76-a731-61a146712527","order_by":10,"name":"Xindi Luan","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Xindi","middleName":"","lastName":"Luan","suffix":""},{"id":339250830,"identity":"5b2b6434-0974-4bbc-9cda-fbda7e1ec4d3","order_by":11,"name":"Yingjue Li","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Yingjue","middleName":"","lastName":"Li","suffix":""},{"id":339250831,"identity":"0a57f21b-fbad-4f3b-9422-1766f4f10183","order_by":12,"name":"Mengde Shi","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Mengde","middleName":"","lastName":"Shi","suffix":""},{"id":339250832,"identity":"a08a80e4-231d-4f92-acb4-664474a3bcbf","order_by":13,"name":"Shuijie Li","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Shuijie","middleName":"","lastName":"Li","suffix":""},{"id":339250833,"identity":"eeb52643-379c-4c8b-ba69-bab10040c643","order_by":14,"name":"Chao Liu","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Chao","middleName":"","lastName":"Liu","suffix":""}],"badges":[],"createdAt":"2024-07-29 07:30:25","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4819905/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4819905/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41388-024-03255-2","type":"published","date":"2024-12-26T05:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":66124015,"identity":"bae02f5b-fc06-48da-bdb1-c3b33147444d","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":502087,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMVK impairs the tumor cell-intrinsic interferon response in MSI CRC. \u003c/strong\u003e(A)Schematic diagram of the impact of cholesterol synthesis pathway on the efficacy of immunotherapy for MSI colorectal cancer and the screening of the specific mediators in the pathway. (B)GSEA enrichment analysis was carried out on the differentially expressed genes in Mevalonate pathway, using the dataset “Hallmark_Interferon Gamma Response”. Bubble colors represent p-value. (C)After interfering with siRNA library in HCT116 cell line, qRT-PCR was used to detect the transcription levels of Th1 type chemokines after IFN-γ stimulation compared to the control group (si-NC). The color of each unit represents the median of three repeated experiments. (D)After using siRNA library to interfere with the expression of different genes, flow cytometry was used to detect changes in Th1 type chemokines secretion levels. The figure shows the median fluorescence intensity in three repeated experiments. (E)Representative immunohistochemistry (IHC) staining images showing MVK,CXCL9,CXCL10 and CD8α expression in MSI CRC tissue from 68 patients and the correlations among them . (Scale bar: 100 µm). (F)qRT-PCR analysis the changes in IFN-γ response in colorectal cancer cell lines after \u003cem\u003eMVK\u003c/em\u003eknockout. Statistical significance is indicated (*p \u0026lt; .05, **p \u0026lt; .01, ***p \u0026lt; .001, ****p \u0026lt; .0001). Stimulant (IFN - γ，100 ng/mL, 30 min).\u003c/p\u003e","description":"","filename":"fig1XXX.png","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/965c1f020855b906a62c257f.png"},{"id":66125680,"identity":"fc53e88c-192b-4a37-bf30-4bab02f2c076","added_by":"auto","created_at":"2024-10-08 02:40:57","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1286542,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMVK influences the growth of MSI CRC via the tumor cell-intrinsic interferon response. \u003c/strong\u003e(A)Schematic diagram of constructing the C57BL/6 mouse subcutaneous transplant tumor model with MC38-\u003cem\u003eMvk(WT/KO)\u003c/em\u003e cells. (B)The comparison of tumor weights across MVK WT/KO groups. (C)The volumes of tumors were assessed every 3 days, beginning 7 days post-injection. (D)Images of subcutaneous transplant tumors from C57BL/6 mice at 19 days after injected with MC38-\u003cem\u003eMvk(WT/KO) \u003c/em\u003ecells. (E-F)Representative immunohistochemistry (IHC) staining images showing MVK,CXCL9,CXCL10 and CD8α expression in subcutaneous transplant tumor and their IHC scores.(Scale bar: 30µm). (G)Number of CD8α positive cells in each group. (H)Schematic diagram of constructing the BALB/c mouse subcutaneous transplant tumor model with CT26\u003csup\u003e\u003cem\u003eMsh2-/-\u003c/em\u003e\u003c/sup\u003e-\u003cem\u003eMvk(WT/KO)\u003c/em\u003e cells. (I)The comparison of tumor weights across MVK WT/KO groups. (J) The volumes of tumors were assessed every 3 days, beginning 7 days post-injection. (K)Images of subcutaneous transplant tumors from BALB/c mice at 19 days after injected with CT26\u003csup\u003e\u003cem\u003eMsh2-/-\u003c/em\u003e\u003c/sup\u003e-\u003cem\u003eMvk(WT/KO) \u003c/em\u003ecells. (L-M)Representative immunohistochemistry (IHC) staining images showing MVK,CXCL9,CXCL10 and CD8α expression in subcutaneous transplant tumor and their IHC scores.(Scale bar: 30µm). (N)Number of CD8α positive cells in each group. (O)Schematic diagram of BALB/c-nude mouse subcutaneous transplant tumor model with MC38-\u003cem\u003eMvk(WT/KO)\u003c/em\u003e cells. (P)The comparison of tumor weights across MVK WT/KO groups.(Q) The volumes of tumors were assessed every 3 days, beginning 7 days post-injection. (R)Images of subcutaneous transplant tumors from BALB/c-nude mice at 19 days after injected with MC38-\u003cem\u003eMvk(WT/KO)\u003c/em\u003e cells. Statistical significance is indicated (*p \u0026lt; .05, **p \u0026lt; .01, ***p \u0026lt; .001, ****p \u0026lt; .0001).\u003c/p\u003e","description":"","filename":"fig2XXX.png","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/39222f38bdaa0990447288ee.png"},{"id":66124014,"identity":"e1873662-d671-4a83-a50d-d41c692ee0dc","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":1197514,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMVK significantly modifies the cytotoxic T lymphocytes (CTL) in MSI CRC tumor. \u003c/strong\u003e(A)Heatmap showing the relative expression of selected markers across cell clusters. (B)t-distributed stochastic neighbor embedding (tSNE) plots of clusters from tumor tissues. (C)Use the same color to represent cell clusters with similar functions. (D)Statistical chart of the proportion of CD8α positive cells in MVK(WT/KO) groups. (F)mIF detection of infiltration of CD3 positive cells and CD8α positive cells in subcutaneous transplant tumors. Randomly select three fields of view from each slice to calculate the average, and select three mice from each group for repeated experiments and statistical analysis.(Scale bar: 100µm). (F)Schematic diagram of the effect of \u003cem\u003eMvk\u003c/em\u003e on tumor growth after antagonizing CD8α positive T cells in C57BL/6 mice. (G)The volumes of tumors were assessed every 3 days, beginning 7 days post-injection. (H)The comparison of tumor weights across MVK WT/KO groups. (I)The image of subcutaneous transplant tumors from C57BL/6 mice at 22 days after injected with MC38-\u003cem\u003eMvk(WT/KO)\u003c/em\u003e cells. Statistical significance is indicated (*p \u0026lt; .05, **p \u0026lt; .01, ***p \u0026lt; .001, ****p \u0026lt; .0001).\u003c/p\u003e","description":"","filename":"fig3XXX.png","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/b516e6e404c9ef9902f908a0.png"},{"id":66125681,"identity":"71649294-6fe4-469f-98c4-8f9b3fe07634","added_by":"auto","created_at":"2024-10-08 02:40:57","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":578991,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMVK impairs the phosphorylation of STAT1 within the interferon response. \u003c/strong\u003e(A)Transfection of RKO and MC38 cell lines using Flag-MVK plasmids or empty vector and detection of marker interactions through CO-IP assay. (B)Transfection of RKO and MC38 cell lines using Flag-STAT1 plasmids or empty vector and detection of marker interactions through CO-IP assay. (C)Confocal immunofluorescence analysis was utilized to detect the localization of MVK and STAT1 in RKO and MC38 cells.Bar scale:10µm. (D)The left figure shows the structural domain of STAT1. CO-IP assay revealed the interaction between STAT1-TAD and MVK in MC38 cells. (E)Transfection of Flag-STAT1 plasmid or empty vector in RKO/MC38-MVK(WT/KO) cell lines and validation of protein interaction through CO-IP assay. (F)Detection of pSTAT1 expression levels in RKO/MC38-MVK(WT/KO) cell lines after IFN-γ stimulation through WB assay. Stimulant (IFN - γ，100 ng/mL, 30 min).\u003c/p\u003e","description":"","filename":"fig4XXX.png","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/5f728bc765091dd140d6aca4.png"},{"id":66126096,"identity":"6b956814-c3cd-4320-b370-ca15201391b8","added_by":"auto","created_at":"2024-10-08 02:48:57","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":932302,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMVK replenishment in MVK-deficient tumor cells re-suppresses the interferon response. (\u003c/strong\u003eA)Cells stably expressing MVK and control cells were treated with IFN-γ; Phosphorylation of stat1 were assessed by western blot analysis. (B)Stable expression of MVK in different cell lines and detection the elevated levels of Th1 type chemokines after IFN-γ using qRT-PCR. (C,G)Schematic diagram of constructing mouse subcutaneous transplantation tumor after stable expression of MVK in different cell lines. (D,H) The volumes of tumors were assessed every 3 days, beginning 7 days post-injection. (E,I)The comparison of tumor weights across MVK OE and control groups. (F,J)Images of subcutaneous transplant tumors from mice at 23 days after injected with cells. (K-L)Multiplexed Immunofluorescence (mIF) detection of infiltration of CD3 positive cells and CD8α positive cells in subcutaneous transplant tumors.(Scale bar: 100µm). Statistical significance is indicated (*p \u0026lt; .05, **p \u0026lt; .01, ***p \u0026lt; .001, ****p \u0026lt; .0001). Stimulant (IFN - γ，100 ng/mL, 30 min).\u003c/p\u003e","description":"","filename":"fig5XXX2.png","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/8a89d37e2a4b3ed0d1b036ca.png"},{"id":66125683,"identity":"ae9b9781-68e2-4046-a7dc-ede3176ce325","added_by":"auto","created_at":"2024-10-08 02:40:57","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":689259,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSuppression of MVK improves the effectiveness of immunotherapy in MSI CRC. \u003c/strong\u003e(A)MC38-\u003cem\u003eMvk(WT/KO)\u003c/em\u003e cells were established in C57BL/6 mice and treated as shown (n=6/group). (B) Tumour growth curves were generated from volumes recorded every 3 days. (C)Tumour weight was measured on day 23 after drug treatment. (D) The expression of MVK,CXCL9,CXCL10 and CD8α in tumor from different treatment groups was detected by immunohistochemistry (IHC) stain. Scale bar: 30 µm. (E)Flow cytometry analysis for IFN-γ and CD8a, select three samples from each group for repeated experiments. (F)MC38 cells were established in C57BL/6 mice and treated as shown (n=6/group). (G) Tumour growth curves were generated from volumes recorded every 3 days. (H)Tumour weight was measured on day 23 after drug treatment. (I) The expression of MVK,CXCL9,CXCL10 and CD8α in tumor from different treatment groups was detected by immunohistochemistry (IHC) stain. Scale bar: 30µm. (J)Flow cytometry analysis for IFN-γ and CD8α, select three samples from each group for repeated experiments.Statistical significance is indicated (*p \u0026lt; .05, **p \u0026lt; .01, ***p \u0026lt; .001, ****p \u0026lt; .0001)\u003c/p\u003e","description":"","filename":"fig6XXX.png","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/c77a1b581613f0b5ac279a8a.png"},{"id":66125682,"identity":"be51103d-c94f-42a0-93eb-89f1280db96f","added_by":"auto","created_at":"2024-10-08 02:40:57","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":974213,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe expression of MVK influences the immunotherapy response in MSI CRC patients. \u003c/strong\u003e(A)Schematic diagram of constructing a hPBMC-PDX model. (B)Tumour growth curves were generated from volumes recorded every 3 days. (C)Tumour weight was measured on day 30 after drug treatment. (D)The hPBMC-PDX tumors in mice derived from Isotype IgG group and anti-PD-1 group. (E)Flow cytometry analysis for IFN-γ and CD8α,select three samples from each group for repeated experiments. (F) The expression of MVK,CXCL9,CXCL10 and CD8α in tumor from different treatment groups was detected by immunohistochemistry (IHC) stain. Scale bar: 30µm. (G)Using liver CT imaging reports to demonstrate the efficacy of anti-PD-1 in three CRC patients. (H-I)Grouping based on the level of MVK expression, and demonstrating the efficacy of anti-PD-1 in both groups of patients. Statistical significance is indicated (*p \u0026lt; .05, **p \u0026lt; .01, ***p \u0026lt; .001, ****p \u0026lt; .0001)\u003c/p\u003e","description":"","filename":"fig7XXX.png","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/a7b29a001a5b21c7ca71ab0f.png"},{"id":72448146,"identity":"5651c11e-fbc2-419c-9744-3c8886f572de","added_by":"auto","created_at":"2024-12-27 08:06:24","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":7059531,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/025129df-3964-4246-bb7d-4a0f06ee47c1.pdf"},{"id":66124020,"identity":"b38b6875-b9dd-4d6a-8d93-b5e75e6046f8","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":15743331,"visible":true,"origin":"","legend":"","description":"","filename":"Sup1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/a5eb0242cba1017d2453723b.pdf"},{"id":66124018,"identity":"1d84256e-dee0-4bdd-be7a-bae41c3be701","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":642547,"visible":true,"origin":"","legend":"","description":"","filename":"Sup2.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/e2d399a04472b5512bd5084e.pdf"},{"id":66124021,"identity":"137a525e-74a9-44b9-b489-8b9c1a613c80","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"pdf","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":11568988,"visible":true,"origin":"","legend":"","description":"","filename":"Sup3.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/c2141d05ed11671a15328015.pdf"},{"id":66124028,"identity":"83d7bf6e-a7c7-43b3-baa1-f39086dc6790","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"pdf","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":24428071,"visible":true,"origin":"","legend":"","description":"","filename":"Sup4.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/4ce6178ca636ac91de4f15ea.pdf"},{"id":66124031,"identity":"83504220-044b-4952-86a1-33dcff7ba1b0","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"pdf","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":2519627,"visible":true,"origin":"","legend":"","description":"","filename":"Sup5.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/99d315a0739d92e4a6d58a4f.pdf"},{"id":66124032,"identity":"1d9aadc4-def8-4a63-8467-9bc0d36cb50e","added_by":"auto","created_at":"2024-10-08 02:32:58","extension":"pdf","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":101267871,"visible":true,"origin":"","legend":"","description":"","filename":"Sup6.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/a349c8e59d77c21f53d69aa8.pdf"},{"id":66124024,"identity":"377b5f2e-110e-406e-844a-1c1c770ef1ff","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"docx","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":15062,"visible":true,"origin":"","legend":"","description":"","filename":"Table1.XXXXXXXXXXXX.docx","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/8e05ba097f871afa5698f55d.docx"},{"id":66126097,"identity":"7c663c57-e47e-4968-a985-81be5bdabdd1","added_by":"auto","created_at":"2024-10-08 02:48:57","extension":"docx","order_by":8,"title":"","display":"","copyAsset":false,"role":"supplement","size":17539,"visible":true,"origin":"","legend":"","description":"","filename":"Table2.siRNAXXXXXX.docx","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/0cdba7c9d07082efdde50be1.docx"},{"id":66125688,"identity":"e58e1adb-6467-4012-8373-c0453995d716","added_by":"auto","created_at":"2024-10-08 02:40:57","extension":"docx","order_by":9,"title":"","display":"","copyAsset":false,"role":"supplement","size":15692,"visible":true,"origin":"","legend":"","description":"","filename":"Table3.XXXXXXpCRXXXXXXXXXXXX.docx","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/74d3c9a3e76dcffc0dcd6551.docx"},{"id":66125685,"identity":"bc3ac7dc-3d22-4fa7-9ff9-ab26f81b83a7","added_by":"auto","created_at":"2024-10-08 02:40:57","extension":"docx","order_by":10,"title":"","display":"","copyAsset":false,"role":"supplement","size":19469,"visible":true,"origin":"","legend":"","description":"","filename":"Table4.XXXXXXXXXXXXXXXXXXXXXXXXXXX.docx","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/a882b8485c6bb570d5741618.docx"},{"id":66124029,"identity":"7074ffca-641e-454b-8b19-94c1a9f1a1aa","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"docx","order_by":11,"title":"","display":"","copyAsset":false,"role":"supplement","size":12974,"visible":true,"origin":"","legend":"","description":"","filename":"Table5.XXXXXXXXXXXX.docx","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/b2014cbae213ba6c9c9b5033.docx"},{"id":66124027,"identity":"4cb4ba01-b90a-437c-a438-e5ddafd2ba57","added_by":"auto","created_at":"2024-10-08 02:32:57","extension":"docx","order_by":12,"title":"","display":"","copyAsset":false,"role":"supplement","size":15971,"visible":true,"origin":"","legend":"","description":"","filename":"Table6.XXXXXXXXXXXX.docx","url":"https://assets-eu.researchsquare.com/files/rs-4819905/v1/ca87bcdae68871fa6a95c205.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose.","formattedTitle":"Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer","fulltext":[{"header":"Introduction","content":"\u003cp\u003eImmune checkpoint blockade (ICB) by the anti-PD-1 monoclonal antibody or anti-CTLA-4 monoclonal antibody, has been approved for treating microsatellite instability colorectal cancer (MSI CRC) \u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]\u003c/sup\u003e. Clinical trials of KEYNOTE-177 and CHECKMATE-142 indicate that half of MSI CRC patients experience limited efficacy from single or dual immunotherapy regimens \u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/sup\u003e. Tumor cell-intrinsic interferon response significantly affects anti-tumor immune resistance and the efficacy of immunotherapy \u003csup\u003e[\u003cspan additionalcitationids=\"CR5 CR6\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]\u003c/sup\u003e. Within the tumor microenvironment, activated T cells and NK cells release IFN-γ, triggering JAK1 and STAT1 phosphorylation and enhancing the transcription of Th1 type cytokines (CXCL9, CXCL10, and CXCL11) and antigen-presenting molecules. This activation pathway can recruit anti-tumor immune cells and bolstering cytotoxic activity \u003csup\u003e[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/sup\u003e. Absence of IFN-γ receptors or mutations in JAK1/STAT1 in tumor cells can suppress T cell-mediated immune responses and lead to immune evasion \u003csup\u003e[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]\u003c/sup\u003e. Furthermore, clinical cohorts of melanoma, non-small cell lung cancer, and MSI CRC all revealed that JAK1 and B2M gene mutations are correlated with the efficacy of ICB therapy \u003csup\u003e[\u003cspan additionalcitationids=\"CR12 CR13\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eAbnormally activated cholesterol synthesis is a metabolic hallmark in colorectal cancer and a crucial mechanism of promoting tumor immune evasion \u003csup\u003e[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]\u003c/sup\u003e. However, the potential crosstalk between the cholesterol synthesis and tumor cell-intrinsic interferon response remains unclear. Mevalonate pathway is the main source of cholesterol synthesis in vivo. Besides the metabolic synthesis functions, several enzymes of mevalonate pathway have been proved affect the conduction of signaling pathways. 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) promotes MYC phosphorylation by stabilizing the activity of RacGTPase, thereby promoting the development of hepatocellular carcinoma \u003csup\u003e[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]\u003c/sup\u003e. Cytochrome P450 family 27 subfamily A member 1 (CYP27A1) overexpresses in various cancers and produces 27-hydroxycholesterol (27HC), 27HC has been demonstrated that can induce AKT activation and the secretion of IL-6, vascular endothelialgrowth factor (VEGF), resulting in CRC development \u003csup\u003e[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]\u003c/sup\u003e. In addition, the knockdown of sterol regulatory element binding transcription factor (SREBP) could suppress tumor growth in xenograft models of colon cancer and downregulate the expression of genes associated with cell stem \u003csup\u003e[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]\u003c/sup\u003e. These findings indicate that cholesterol metabolizing enzymes may impact interferon reactivity through non-biochemical mechanisms.\u003c/p\u003e \u003cp\u003eIn this study, we identified MVK was the key medium in the crosstalk between cholesterol metabolism and the tumor cell-intrinsic interferon response. We sought to demonstrate the underlying mechanism by which MVK affects interferon reactivity in both vitro and vivo. Finally, the expression level of MVK and the efficacy of ICB therapy were demonstrated in animal models and clinical cohorts. Our current study is promising to explain the limited effectiveness of ICB therapy in some MSI CRC patients from the perspective of abnormal cholesterol metabolism affecting interferon reactivity. This is expected to provide theoretical support for the development of targeted MVK-sensitizing ICB therapies.\u003c/p\u003e"},{"header":"Material and Methods","content":"\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eCell culture, Reagents, and antibodies\u003c/h2\u003e \u003cp\u003eHuman cell lines (CCD-841CoN,RKO,HCT15,HT29,HCT116,SW48,SW620,SW480 SW948,DLD1) and mouse cell lines(MC38,CT26) were acquired from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China).These cell lines were routinely authenticated by quality examinations of morphology and short tandem repeat (STR) markers by the supplier.All cells were mycoplasma-free and cultured in RPMI 1640 medium (Gibco, USA) or DMEM medium (Gibco, USA), containing 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin (Gibco United States). All cells were kept at 37\u0026deg;C in a humidified incubator supplied with 5% CO2.\u003c/p\u003e \u003cp\u003eThe CRISPR/Cas9 technology were using to create CT26 \u003cem\u003eMsh2\u003c/em\u003e-knockout cells. Plasmids containing GFP, Cas9 and puromycin resistance markers, and single guide RNAs (sgRNA) targeting exon 2 of mouse MSH2 (the sequences are sg1:5\u0026rsquo;-CCTGGGTCTTGAACACCTCG-3\u0026rsquo;; sg2:5\u0026rsquo;-GGGCTTCGTGCGCTTCTTTG-3\u0026rsquo;) were cotransfected into CT26 cells. The transfected cells were treated with puromycin (2 \u0026micro;g/ml) and selected by FACS. Cell clones were enriched in 96-wells plates. The qRT-PCR and western blot analysis were used to verify the expression of MSH2 .\u003c/p\u003e \u003cp\u003eThe antibodies involved are listed in Supplementary Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e,and drugs utilised in this work include Atorvastatin (S5715, Selleck), IFN-γ (I17001/I4777, Sigma), Anti-mouseCD8α-inVivo(A2102, Selleck), Anti-mousePD1-inVivo(A2122, Selleck).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003ePatients and Clinical Specimens\u003c/h2\u003e \u003cp\u003eThe colorectal tumours and paired normal tissues were collected from 68 MSIH-H CRC patients who underwent radical resection in the Department of Colorectal Surgery, Harbin Medical University Affiliated Cancer Hospital. The patients detailed statistics are provided in Table \u003cspan refid=\"MOESM5\" class=\"InternalRef\"\u003eS5\u003c/span\u003e. Serum samples were obtained from 3 patients of CRC. Informed written consents were obtained from all subjects.\u003c/p\u003e \u003cp\u003eNone of the patients in this study had undergone prior surgeries or been taking any medication. The research protocol involving human conforms to the principles of the Helsinki Declaration and was approved by the Clinical Research Ethics Committee of the Cancer Hospital affiliated with Harbin Medical University.(Approval number:KY2023-57)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003ePlasmid and truncated protein\u003c/h2\u003e \u003cp\u003eThe full-length myc/flag-tagged human MVK/STAT1 cDNA were obtained from General Biology(Anhui, China). The myc/flag-tagged mouse Mvk cDNA are synthesized in laboratory based on the transcripts from NCBI database, using the pCDH-EF1-MCS-CMV-copGFP-T2A-Puro vector General Biology(Anhui, China).Sequences of the transcriptss used for plasmid construction are listed in Supplementary Table \u003cspan refid=\"MOESM4\" class=\"InternalRef\"\u003eS4\u003c/span\u003e.\u003c/p\u003e \u003cp\u003eUsing the plasmid of wildtype human STAT1 as the template, truncate five structural domains separately(TAD:between amino acids from 683 to 750)(SH2:between amino acids from 481 to 683)(DBD:between amino acids from 317 to 481)(CCD:between amino acids from 138 to 317)(NT:between amino acids from 1 to 138). All sequences of truncated proteins are listed in Supplementary Table \u003cspan refid=\"MOESM4\" class=\"InternalRef\"\u003eS4\u003c/span\u003e.\u003c/p\u003e \u003cp\u003eAdditionally, the siRNAs of human \u003cem\u003eMVK, MVD, FDFT1, ACAT2, GGPS1, FDPS, PMVK, HMGCR, HMGCS1\u003c/em\u003e and \u003cem\u003eIDI1\u003c/em\u003e were obtained from General Biology(Anhui,China). (Supplementary Table \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003e-siRNA sequences).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eLentivirus transduction and CRISPR‒Cas9 gene editing\u003c/h2\u003e \u003cp\u003eWe used pCDH-EF1-MCS-CMV-copGFP-T2A-Puro lentiviral vectors obtained from General Biology(Anhui,China) to clone \u003cem\u003eMVK\u003c/em\u003e sequences. The lentivirus were subsequently used to package the vectors and infected cells for six hours. The MVK overexpressing cells were selected by medium containing puromycin (Sigma).\u003c/p\u003e \u003cp\u003eThe CRISPR/Cas9 technology were using to create \u003cem\u003eMVK\u003c/em\u003e-knockout cells. Plasmids containing GFP, Cas9 and puromycin resistance markers, and single guide RNAs (sgRNA) targeting exon 2 of mouse \u003cem\u003eMVK\u003c/em\u003e were cotransfected into cells for 24h. The transfected cells were treated with puromycin (2 \u0026micro;g/ml) and selected by FACS. Cell clones were enriched in 96-wells plates. The qRT-PCR and western blot analysis were used to verify the expression of MVK after 14\u0026thinsp;\u0026minus;\u0026thinsp;20 days.(Supplementary Table \u003cspan refid=\"MOESM4\" class=\"InternalRef\"\u003eS4\u003c/span\u003e-sgRNA sequences).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eCo-immunoprecipitation\u003c/h2\u003e \u003cp\u003eFor co-immunoprecipitation (Co-IP), the 1mL lysis buffer were used to treat 10\u003csup\u003e6\u003c/sup\u003e cells on ice for 20 min and centrifuged at 12,000 rpm for 15 min at 4℃. The supernatant was incubated with 50\u0026micro;L anti DYKDDDDK magnetic agarose suspension (A36798, ThermoFisher) for 30 minutes at room temperature, followed by collecting magnetic agarose with Magnetic frame.After washing by lysis buffer, magnetic agarose were boiled with 5x loading buffer for 10 min followed by western blotting analyse.\u003c/p\u003e \u003cp\u003eThe plasmid of flag-tagged STAT1 and flag-tagged truncations, were transiently transfected with transfection reagent for 48 h. Cells were lysed bt radioimmunoprecipitation assay (RIPA) buffer in the presence of complete protease inhibitors and used anti DYKDDDDK magnetic agarose for immunoprecipitation.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eMulti-color IHC (mIHC)\u003c/h2\u003e \u003cp\u003eFormalin-fixed paraffin-embedded tissue (FFPE) sections from subcutaneous transplant tumor tissue were cut in 4\u0026micro;m serial sections. Conduct antigen retrieval using the immunohistochemical protocol until the primary antibodies were incubated (Primary antibodies included CD3 and CD8a). Subsequently, multi-color IHC was performed using the five-color multiplex fluorescent immunohistochemical staining kit (abs50013, ABSIN). The position of the primary antibodies binding specific antigen were paired to TSA fluorophore from the kit. All fluorophores and DAPI were prepared according to manufacturer guidelines. For multiple fluorescent staining, sections were processed starting from the antigen retrieval step to remove binding antibodies, and then they were incubated with another primary antibody. This was repeated until all antigens were stained. Finally, counterstaining was performed with DAPI and anti-fluorescence quenching blocker was added dropwise. Images were captured using an Olympus BX53 microscope under suitable laser excitation conditions.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eMass Cytometry\u003c/h2\u003e \u003cp\u003eStain 6 to 11\u0026nbsp;million Percoll-enriched cells with 0.5mM cisplatin in 1mL PBS (without Ca2\u0026thinsp;+\u0026thinsp;and Mg2+) at room temperature for 2 minutes. Add 2mL of cell staining buffer (Fluidigm, catalog number 201068) to halt the reaction, and centrifuge the mixture at 500 \u0026times; g for 5 minutes. Following Fc blockade (BioLegend, Cat # 422302), the cells were incubated with a cocktail of metal-labeled antibodies, including 41 types (Supplementary Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e.), at room temperature for 30 minutes. After washing with the cell staining buffer, the cells were incubated with 125mM Intercator Ir (Fluidigm, Cat # 201192A) in fixed and osmotic buffer (Fluidigm, Cat # 201067) at room temperature for 1 hour. Subsequently, wash the cells twice with Maxpar water (Fluidigm, Cat # 201069), mix with EqBeads (Fluidigm, Cat # 201078), and analyze on a CyTOF Helios machine. Refer to Supplementary Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e for the detailed staining protocol.\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section3\"\u003e \u003ch2\u003eConstruction of hPBMC-PDX model and therapeutic experiments in vivo\u003c/h2\u003e \u003cp\u003eImmediately following surgical removal, fresh colorectal cancer tumor samples were collected and transported in cold complete culture medium. The tissue was then sectioned into 2-3mm pieces and implanted into NYG mice from Charles River (Beijing, China), which are immunodeficient due to knockout mutations in Prkdc and Il2rg genes. The growth of the xenografts was monitored twice weekly using calipers, and subsequent passaging commenced once the tumor volume reached approximately 0.1 cm\u003csup\u003e3\u003c/sup\u003e.Upon reaching the third passage, inject human PBMCs (approximately 5 x 10\u003csup\u003e6\u003c/sup\u003e) into NYG mice, to create a humanized PBMC-PDX model. Suspend the human PBMCs at a density of 4 x 10\u003csup\u003e6\u003c/sup\u003e cells per 0.1 ml in sterile phosphate-buffered saline and inject them intraperitoneally with a 1-cc tuberculin syringe.NYG mice can receive donor PBMCs that match or do not match the PDX implanted in their bodies. Donor blood samples do not require HLA typing.\u003c/p\u003e \u003cp\u003eApproximately 2 weeks after injection, perform flow cytometry analysis to assess the human cells in the mice. Mice with a human CD45\u0026thinsp;+\u0026thinsp;cell percentage of \u0026gt;\u0026thinsp;1% are included in the experimental group. Monitor the health status of mice daily following human cell implantation. Based on the growth rate of huPBMC-PDX, mice were randomly added to treatment group and control group when the size of tumour reached 0.1 cm\u003csup\u003e3\u003c/sup\u003e approximately. The hPBMC-PDX model was raised in the pathogen-free environment. Treatment groups received the following: Anti mouse PD-1 monoclonal antibody in vivo (0.2 mg/mice, twice a week, i.p.) or PBS. Each experimental group includes 3 mice with Unilateral implanted tumors. Record tumor growth every 3 to 4 days and calculate tumor volume using the formula V=(length x width\u003csup\u003e2\u003c/sup\u003e). If the tumor's size exceeds 1.5 centimeters in any dimension, the mouse will be humanely euthanized.(Approval number:KY2023-57)\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eSubcutaneous transplantation tumor model in mice and therapeutic experiments\u003c/h2\u003e \u003cp\u003eSix-week-old female C57BL/6,BALB/c,and BALB/c-nude mice obtained form Charles River(Beijing,China) were subcutaneously injected with 1 \u0026times; 10\u003csup\u003e6\u003c/sup\u003e cells into the right flank.Upon tumour formation, treatment was initiated with Anti mouse PD-1 monoclonal antibody in vivo (0.2 mg/mice, twice a week, i.p.); Atorvastatin (0.2 mg/mice daily, p.o.); Anti mouse PD-1 monoclonal antibody in vivo (0.2 mg/mice, twice a week, i.p.)\u0026thinsp;+\u0026thinsp;Atorvastatin (0.2 mg/mice daily, p.o.).Tumour dimensions were consistently monitored every other day using Vernier callipers, and the volume was calculated using the formula: V = [length \u0026times; (width)\u003csup\u003e2\u003c/sup\u003e]/2. Mice were euthanised if the tumour lengths exceeded 1.5 cm in any direction. (Approval number:KY2023-57)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eThe mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation denotes the presentation of quantitative data. GraphPad Prism (RRID: SCR_002798) was employed to assess statistical significance using a two-tailed unpaired Student's t-test. Statistical significance is defined as p-values less than 0.05: p\u0026thinsp;\u0026lt;\u0026thinsp;0.05, p\u0026thinsp;\u0026lt;\u0026thinsp;0.01, and p\u0026thinsp;\u0026lt;\u0026thinsp;0.001. At least three independent biological replicates were used in each experiment. The R value is determined by Spearman correlation analysis.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003e1.MVK impairs the tumor cell-intrinsic interferon response in MSI CRC\u003c/h2\u003e \u003cp\u003eTo identify the specific mediators involved in cholesterol synthesis and the tumor cell-intrinsic interferon response, we conducted a screening of the key enzymes within the mevalonate pathway, using both siRNA library and GSEA (Fig.\u0026nbsp;1A, Sup1A). We assessed the gene expression levels of these enzymes and their enrichment with the interferon signaling pathway from the TCGA-CRC cohort, identifying the MVK having the highest enrichment score (Fig.\u0026nbsp;1B). Additionally, we employed siRNA to interfere with the expression of the enzymes in the MSI CRC cell line HCT116 (Sup1B), and assessed alterations in the expression levels of Th1 type cytokines (CXCL9 and CXCL10) using qRT-PCR and flow cytometry. The findings revealed that, disrupting MVK expression led to the most pronounced elevation in CXCL9 and CXCL10 levels (Fig.\u0026nbsp;1C, 1D). Subsequently, we gathered paraffin-embedded tumor samples of 68 MSI CRC patients, along with adjacent normal specimens, and discovered that within MSI CRC tumor tissues, higher MVK expression levels correlated with lower levels of CXCL9 and CXCL10, and reduced infiltration of CD8\u003csup\u003e+\u003c/sup\u003eT cells (Fig.\u0026nbsp;1E). Analysis of transcriptome data from the TCGA-CRC database further validated these findings (Sup1C). We assessed the basal expression of MVK in various human MSI CRC cell lines and three enterocyte lines (Sup1E). We selected two cell lines with high basal MVK expression along with two mouse colorectal cancer cell lines, and used CRISPR-Cas9 to knock out the MVK gene (Sup1H). In these four MVK-knockout cell lines, we observed a significant increase in the transcription levels of CXCL9 and CXCL10 following IFN-γ stimulation, compared to the MVK wild-type (Fig.\u0026nbsp;1F). Regarding the basal expression of MVK, the results were consistent with the variations noted in the TCGA-CRC database (Sup1D), the WB and IHC analysis also revealed that MVK expression was significantly higher in colorectal cancer tissues than in normal tissues (Sup1F-G).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003e2.MVK influences the growth of MSI CRC via the tumor cell-intrinsic interferon response\u003c/h2\u003e \u003cp\u003eTo verify the potential influence of MVK on the progression of CRC cells, we compared the growth and migration of CRC cell lines in vitro with CCK-8 and cell migration assay. The results indicate that no differences in proliferation and migration of these MSI CRC cells following MVK gene knockout (Sup2A-H). In vivo experiments, we established mouse subcutaneous transplant tumor models (Fig.\u0026nbsp;2A, H) using the MC38-\u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eWT/KO\u003c/sup\u003e and CT26\u003csup\u003e\u003cem\u003eMsh2\u003c/em\u003e−/−\u003c/sup\u003e-\u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eWT/KO\u003c/sup\u003e cell lines. We observed that the tumors generated by the \u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eKO\u003c/sup\u003e cell lines were significantly suppressed in both growth rate and tumor weight compared to the control cell lines (\u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eWT\u003c/sup\u003e) (Fig.\u0026nbsp;2B-D, Fig.\u0026nbsp;2I-K). To reconfirm the impact of MVK on the tumor cell-intrinsic interferon response in vivo, the IHC revealed a significant increase in the number of CD8\u003csup\u003e+\u003c/sup\u003eT cells and expression of CXCL9 and CXCL10 within all subcutaneous transplant tumors derived from the \u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eKO\u003c/sup\u003e cell lines(Fig.\u0026nbsp;2E-G,Fig.\u0026nbsp;2L-N). The qRT-PCR experiments demonstrate that the transcription level of the CXCL9 and CXCL10 in subcutaneous transplanted tumors is significantly elevated as a result of MVK knockout (Sup2I-J). However, when we injected the MC38-\u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eWT/KO\u003c/sup\u003e cell lines into BALB/c-nude mice which lacking intact immune system (Fig.\u0026nbsp;2O), we observed no differences in tumor growth among these immunodeficient mice (Fig.\u0026nbsp;2P-R), indicating that the inhibition of MVK on MSI CRC growth is dependent on the intact immune system.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003e3.MVK significantly modifies the cytotoxic T lymphocytes (CTL) in MSI CRC tumor\u003c/h2\u003e \u003cp\u003eTo investigate the specific impact of MVK on MSI CRC, we conducted mass cytometry analysis (Fig.\u0026nbsp;3A-B) on MC38-\u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eWT/KO\u003c/sup\u003e subcutaneous transplanted tumors from C57BL/6 mice. These tumor-infiltrating lymphocytes were segmented into distinct subgroups based on the cell surface markers (Fig.\u0026nbsp;3A-B). Within the \u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eKO\u003c/sup\u003e group, we observed a significant elevation in the number of T cell subset, particularly CD8\u003csup\u003e+\u003c/sup\u003eT cells (Fig.\u0026nbsp;3C). Additionally, these T cells displayed a notable upregulation in the expression of effector molecules, such as IFN-γ and GZMB (Fig.\u0026nbsp;3D). We also stained the subcutaneous transplanted tumors from each group and detected a marked increase in CD8\u003csup\u003e+\u003c/sup\u003eT cells within the MVK knockout group via flow cytometry (Sup3A). Concurrently, mIF revealed that, compared to MVK wild-type tumors, the MVK knockout group exhibited a substantial rise in the numbers of CD3 and CD8 cells within the tumor center, though these differences were not apparent at the tumor margins (Fig.\u0026nbsp;3E). To further validate the role of MVK in influencing tumor growth via CD8 + T cells, we administered anti-CD8a antibodies to the \u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eWT/KO\u003c/sup\u003e group, effectively depleting CD8\u003csup\u003e+\u003c/sup\u003eT cells (Sup3E). Our results demonstrate that, following the depletion of CD8 + T cells, the subcutaneous transplanted tumors in the MVK knockout group resumed their growth (Fig.\u0026nbsp;3F-I). To exclude the interference caused by potential changes in tumor immunogenicity, we employed immunofluorescence to assess γ-H2AX expression and whole exome sequencing to monitor alterations in genomic mutation levels in both \u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eWT\u003c/sup\u003e and \u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eKO\u003c/sup\u003e cell lines. These experiments revealed no significant differences in DNA damage or exon mutation rates in cells with MVK knocked out (Sup3B-D).\u003c/p\u003e \u003cp\u003e4.\u003cb\u003eMVK impairs the phosphorylation of STAT1 within the interferon response\u003c/b\u003e\u003c/p\u003e \u003cp\u003eWe further explored the mechanism of MVK regulating the interferon response. Initially, we transfected the Flag-MVK plasmid into the human cell line RKO and the mouse cell line MC38, and verified the interactions among key proteins in the interferon signaling pathway using CO-IP experiments (Sup4A). The WB revealed an interaction between MVK and STAT1 protein (Fig.\u0026nbsp;4A). Subsequently, when we transfected the Flag-STAT1 plasmid for CO-IP experiments, we have observed the same result (Fig.\u0026nbsp;4B). Additionally, using IF we demonstrated the co-localization of STAT1 and MVK proteins in cytoplasm (Fig.\u0026nbsp;4C). STAT1 comprises five distinct functional domains \u003csup\u003e[\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]\u003c/sup\u003e. To clarify how MVK influences STAT1's function, we reconstructed five truncated forms of STAT1 (Fig.\u0026nbsp;4D). The CO-IP experiments revealed that MVK binds to the TAD region of STAT1. Using the AlphaFold2 website to predict protein-protein interactions, we discovered a high level of interaction between MVK and the TAD region of STAT1(Sup4B). We transfected the Flag-STAT1 plasmid into both MVK knockout and wild-type of RKO and MC38. Co-IP experiments revealed a significant increase in the binding levels of STAT1 and JAK1 proteins in the MVK knockout strains (Fig.\u0026nbsp;4E). Following stimulation with IFN-γ, a notable elevation in the phosphorylation levels of STAT1 was observed in the MVK knockout strains (Fig.\u0026nbsp;4F). Additionally, through Lucifer and IF assays, we observed that the nuclear accumulation of pSTAT1 was significantly higher in MVK-knockout cells compared to the control group after IFN-γ stimulation (Sup4C- D). Intriguingly, after adding atorvastatin, a clinically prescribed cholesterol-suppressing drug, to the culture medium for colorectal cancer cells, we observed a dose-dependent reduction in MVK expression levels. And subsequently led to heightened levels of STAT1 and JAK1 protein binding (Sup4E).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003e5.MVK replenishment in MVK-deficient tumor cells re-suppresses the interferon response\u003c/h2\u003e \u003cp\u003eTo verified the function of MVK impacting interferon response, we leveraging the \u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eKO\u003c/sup\u003e cell lines established in Fig.\u0026nbsp;1 to generate stable MVK over-expressing lines through lentivirus. We observed that rescuing MVK significantly reduced the phosphorylation levels in cells stimulated with IFN-γ, without affecting the baseline expression of STAT1 (Fig.\u0026nbsp;5A). To further confirm the tumor cell-intrinsic interferon response in MSI CRC, we utilized that rescuing MVK significantly attenuated the upregulation of CXCL9 and CXCL10 RNA levels following interferon stimulation (Fig.\u0026nbsp;5B). In vivo experiments, we observed that subcutaneous transplanted tumors with the wild-type MVK experienced accelerated growth following MVK overexpression. Subcutaneous transplanted tumors with MVK knockdown resumed growth following restoration of MVK expression (Fig.\u0026nbsp;5C-J). We then performed mIF experiments on the subcutaneous transplanted tumors. Within the tumor microenvironment, the restoration of MVK expression led to a significant reduction in the numbers of CD3 and CD8\u003csup\u003e+\u003c/sup\u003eT cells (Fig.\u0026nbsp;5K-L). The IHC experiments have also demonstrated similar alterations in the level of CXCL9, CXCL10 and CD8\u003csup\u003e+\u003c/sup\u003eT, potentially contributing to the resumed tumor growth in mice (Sup5A-D).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003e6.Suppression of MVK improves the effectiveness of immunotherapy in MSI CRC\u003c/h2\u003e \u003cp\u003eWe postulate whether inhibiting MVK expression might enhance T cell infiltration and improve the effectiveness of ICB immunotherapy. For this purpose, we established subcutaneous transplant tumor models with \u003cem\u003eMvk\u003c/em\u003e\u003csup\u003eWT/KO\u003c/sup\u003e cells in C57BL/6 and BALB/C mice, and treated them with anti-PD-1 monoclonal antibodies (Fig.\u0026nbsp;6A, Sup6A). The results revealed that in these mouse tumor models, the MVK knockout group demonstrated significantly greater anti-PD-1 therapeutic efficacy compared to the wild-type group (Fig.\u0026nbsp;6B-C and Sup6B-C). We further analyzed tumor tissues using IHC and flow cytometry, and consistent with our prior findings, the MVK knockout group displayed increased levels of Th1 chemokines and CTL cells, which contribute to the superior immune therapeutic response (Fig.\u0026nbsp;6D-E and Sup6D-E). Considering the inhibitory effect of statins on MVK (Sup4E), we unexpectedly discovered that atorvastatin suppresses the expression of MVK. Consequently, we conducted experiments in vivo to investigate the sensitizing effect of atorvastatin on ICB efficacy (Fig.\u0026nbsp;6F and Sup6F), revealing that, while atorvastatin lacks intrinsic antitumoral activity, it significantly enhances the therapeutic efficacy of anti-PD-1 monoclonal antibodies (Fig.\u0026nbsp;6G-J and Sup6G-J).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003e7.The expression of MVK influences the immunotherapy response in MSI CRC patients\u003c/h2\u003e \u003cp\u003eBased on the experimental results above, we constructed a hPBMC-PDX model with human immune system to further assess the impact of MVK on the immunotherapy for MSI CRC patients. The hPBMC-PDX model was randomly assigned to either the treatment or control group and treated with PD-1 monoclonal antibody (Fig.\u0026nbsp;7A). The results demonstrated that the hPBMC-PDX models with low MVK expression exhibited superior immunotherapy efficacy compared to those with high MVK expression (Fig.\u0026nbsp;7B-D). Analysis of the tumor micro-environment revealed a significant increase in the proportion of CLT cells and Th1 type chemokines in the tumor tissues of mice with low MVK expression levels (Fig.\u0026nbsp;7E-F). Furthermore, our follow-up observations on the immunotherapy efficacy in the three parental patients. The imaging results indicate that compared with patients with high MVK expression, patients with low MVK expression have a more significant reduction in liver metastasis and exhibit better treatment responsiveness after anti-PD-1 treatment(Fig.\u0026nbsp;7G). To further assess the clinical relevance, we gathered imaging examination and paraffin-embedded tumor tissue samples from 14 MSI CRC patients who undergone immunotherapy at our center. The therapeutic efficacy was assessed using CT scans, and patients were categorized based on their MVK immunohistochemical scores (Fig.\u0026nbsp;7F). Our findings revealed that patients with low MVK expression demonstrated significantly greater sensitivity to immunotherapy compared to those with high MVK expression, with notably elevated proportions of PR and CR patients (Fig.\u0026nbsp;7H-I).\u003c/p\u003e \u003c/div\u003e "},{"header":"Discussion","content":"\u003cp\u003eTumor cells influences the anti-tumor immune response through abnormal cholesterol metabolism. For instance, cholesterol induces the expression of molecules like LAG-3 and PD-1 on CD8\u003csup\u003e+\u003c/sup\u003e T cells, leading to T cell exhaustion and subsequently diminishing immunotherapy outcomes in melanoma \u003csup\u003e[\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]\u003c/sup\u003e. In thymus, cholesterol specifically downregulates T cell signaling and impedes T cell maturation through a complex with TCR-CD3 \u003csup\u003e[\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]\u003c/sup\u003e. Besides the direct impact of cholesterol on cancer immunotherapy, numerous key enzymes within mevalonate pathway are also implicated in crosstalk with several signaling pathways. Knockdown of the geranylgeranyl diphosphate synthase 1 (GGPS1) gene markedly influences the membrane localization and activity of KRAS in CRC cells \u003csup\u003e[\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]\u003c/sup\u003e. HMGCS1 activates the pyroptosis pathway in ovarian cancer, thereby enhancing the effectiveness of immunotherapy \u003csup\u003e[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]\u003c/sup\u003e. Sterol regulatory element binding transcription factor 2 (SREBF2) enhances liver metastasis of rectal cancer via the activation of the PI3K-AKT-mTOR signaling pathway \u003csup\u003e[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eResistance to ICB therapy is partly due to the inadequate intrinsic interferon response in tumor cells \u003csup\u003e[\u003cspan additionalcitationids=\"CR27 CR28\" citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e–\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]\u003c/sup\u003e. Exome sequencing in melanoma reveals that patients resistant to ICB frequently display mutations in the JAK1, JAK2, and β-2 microglobulin(B2M) genes. The mutated JAK1 in these patients fails to upregulate the expression of ISG genes following IFN-γ stimulation \u003csup\u003e[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e–\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]\u003c/sup\u003e. Furthermore, reduced expression levels of genes like IFNGR1, JAK1, and STAT1 can significantly impact the survival of melanoma patients \u003csup\u003e[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]\u003c/sup\u003e. Liao et al. also discovered that USP4 disrupts the interferon response in colorectal cancer cells, resulting in ineffective immunotherapy \u003csup\u003e[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]\u003c/sup\u003e. Therefore, an inadequate intrinsic interferon response in tumor cells represents a limiting factor for ICB treatment. In our research, employing the small interfering RNA library, we identified MVK, a key enzyme in the mevalonate pathway, significantly impacting the intrinsic interferon response of tumor cells.\u003c/p\u003e\u003cp\u003eMVK has been demonstrated to be highly expressed in gastric cancer and prostate cancer, and significantly impacting patients' 5-year overall survival \u003csup\u003e[\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e–\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]\u003c/sup\u003e. In this study, we discovered that MVK expression is markedly elevated in CRC, yet its effect does not depend on influencing tumor cell proliferation or invasion. The mouse subcutaneous tumor models also indicate that MVK primarily affects MSI CRC via the intact immune system. Mechanistically, MVK knockout markedly enhanced the abundance of CD8\u003csup\u003e+\u003c/sup\u003eT cells. Prior research has indicated that the increase of CD8 + T cells within the tumor micro-environment correlates with the generation of neoantigens, and both DNA damage and exon mutations in tumor cells have the potential to elevate neoantigen levels \u003csup\u003e[\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e–\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]\u003c/sup\u003e. We also clariid that there are no differences in neoantigen levels. We found that MVK binds to the TAD of STAT1, disrupting the phosphorylation cascade between JAK1 and STAT1. This interaction subsequently diminishes the nuclear translocation of STAT1. Ultimately, this impaired the interferon response within tumor cells, rendering the ICB treatment ineffective. Furthermore, we observed a significant correlation between MVK expression levels and the effectiveness of immunotherapy for MSI CRC in clinical cohorts.\u003c/p\u003e\u003cp\u003eAs the inhibitor of mevalonate pathway, statins inhibit tumor cell proliferation, promote tumor cell apoptosis, modulate inflammation, endothelial function, and angiogenesis \u003csup\u003e[\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e–\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]\u003c/sup\u003e. Mechanistically, when statins inhibit the mevalonate pathway, they concurrently decrease the production of intermediates such as isoprene, farnesyl pyrophosphate, and geranyl pyrophosphate. These products are closely linked to the activation of small G proteins like Ras and Rho \u003csup\u003e[\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e–\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]\u003c/sup\u003e. In CRC, using statins either alone or in conjunction with celecoxib, has been shown to decrease polyp formation in genetically susceptible mice with multiple intestinal neoplasia(Min) mouse \u003csup\u003e[\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e–\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]\u003c/sup\u003e. Leveraging the pleiotropic properties of statins, our study discovered that these drugs can suppress the expression of the MVK. We proposed the scientific hypothesis for combined statin and immunotherapy, which was further validated through enhanced therapeutic efficacy observed in mouse subcutaneous tumor model. Nonetheless, this study mainly focuses on atorvastatin, while other statin drugs have not been included. In addition, the precise mechanism by which statins inhibit MVK expression also worth further exploration.\u003c/p\u003e\u003cp\u003e \u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003eTo clarify the mechanism of cholesterol in modulating the interferon response of MSI CRC cells. W\u003c/span\u003ee identified the MVK, a key enzyme in cholesterol synthesis, disrupts the interferon response of colorectal cancer cells via its non-biochemical function. This crosstalk ultimately diminishes the effectiveness of ICB therapy. Consequently, this research offers the novel targets to enhance the efficacy of immunotherapy for MSI CRC, also positioning MVK as a potential biomarker for predicting the immunotherapeutic prognosis in MSI CRC.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eThese authors contributed equally\u003c/p\u003e\n\u003ch2\u003eConflicts of Interest\u003c/h2\u003e\n\u003cp\u003eThe authors declare they have no conflicts of interest\u003c/p\u003e\u003ch2\u003eAcknowledgements:\u003c/h2\u003e \u003cp\u003eWe express our heartfelt gratitude to Professor Shuijie Li of Harbin Medical University for his guidance and invaluable advice on this work. Funding for this work was provided by grants from the National Natural Science Foundation of China (nos. U22A20330, 82173233, 82373372, and 82102858), the Key Project of Research and Development Plan in Heilongjiang Province (no. 2022ZX06C01, JD2023SJ40), the Natural Science Funding of Heilongjiang (no. YQ2022H017) and Haiyan Research Fund of Harbin Medical University Cancer Hospital (JJJQ2024-02).\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eAsaoka Y, Ijichi H, Koike K. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;373(20):1979.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDiaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659\u0026ndash;670.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022;40(2):161\u0026ndash;170.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePitt JM, V\u0026eacute;tizou M, Daill\u0026egrave;re R, Roberti MP, Yamazaki T, Routy B, et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity. 2016;44(6):1255\u0026ndash;1269.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022;40:45\u0026ndash;74.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397\u0026ndash;404.e9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, et al. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8:15440.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u0026ndash;572.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u0026ndash;47.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2017;7(2):188\u0026ndash;201.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThompson JC, Davis C, Deshpande C, Hwang WT, Jeffries S, Huang A, et al. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J Immunother Cancer. 2020;8(2):e000974.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819\u0026ndash;829.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBortolomeazzi M, Keddar MR, Montorsi L, Acha-Sagredo A, Benedetti L, Temelkovski D, et al. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. Gastroenterology. 2021;161(4):1179\u0026ndash;1193.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang C, Li D, Xiao B, Zhou C, Jiang W, Tang J, et al. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy. J Immunother. 2022;45(4):187\u0026ndash;193.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJun SY, Brown AJ, Chua NK, Yoon JY, Lee JJ, Yang JO, et al. Reduction of Squalene Epoxidase by Cholesterol Accumulation Accelerates Colorectal Cancer Progression and Metastasis. Gastroenterology. 2021;160(4):1194\u0026ndash;1207.e28.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMa X, Bi E, Lu Y, Su P, Huang C, Liu L, et al. Cholesterol Induces CD8\u0026thinsp;+\u0026thinsp;T Cell Exhaustion in the Tumor Microenvironment. Cell Metab. 2019;30(1):143\u0026ndash;156.e5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu J, Liu N, Song D, Steer CJ, Zheng G, Song G. A positive feedback between cholesterol synthesis and the pentose phosphate pathway rather than glycolysis promotes hepatocellular carcinoma. Oncogene. 2023;42(39):2892\u0026ndash;2904.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXiao W, Hu C, Ni Y, Wang J, Jiao K, Zhou M, et al. 27-Hydroxycholesterol activates the GSK-3β/β-catenin signaling pathway resulting in intestinal fibrosis by inducing oxidative stress: effect of dietary interventions. Inflamm Res. 2024;73(2):289\u0026ndash;304.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWen YA, Xiong X, Zaytseva YY, Napier DL, Vallee E, Li AT, et al. Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer. Cell Death Dis. 2018;9(3):265.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePhilips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell. 2022;185(21):3857\u0026ndash;3876.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMa X, Bi E, Lu Y, Su P, Huang C, Liu L, et al. Cholesterol Induces CD8\u0026thinsp;+\u0026thinsp;T Cell Exhaustion in the Tumor Microenvironment. Cell Metab. 2019;30(1):143\u0026ndash;156.e5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang F, Beck-Garc\u0026iacute;a K, Zorzin C, Schamel WW, Davis MM. Inhibition of T cell receptor signaling by cholesterol sulfate, a naturally occurring derivative of membrane cholesterol. Nat Immunol. 2016;17(7):844\u0026ndash;850.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJia WJ, Jiang S, Tang QL, Shen D, Xue B, Ning W, et al. Geranylgeranyl Diphosphate Synthase Modulates Fetal Lung Branching Morphogenesis Possibly through Controlling K-Ras Prenylation. Am J Pathol. 2016;186(6):1454\u0026ndash;1465.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell. 2023;41(4):740\u0026ndash;756.e10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang KL, Zhu WW, Wang SH, Gao C, Pan JJ, Du ZG, et al. Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics. 2021;11(13):6560\u0026ndash;6572.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlbacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS One. 2017;12(11):e0176181.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDu W, Hua F, Li X, Zhang J, Li S, Wang W, et al. Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. Cancer Discov. 2021;11(7):1826\u0026ndash;1843.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMiddha S, Yaeger R, Shia J, Stadler ZK, King S, Guercio S, et al. Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precis Oncol. 2019;3:PO.18.00321.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819\u0026ndash;829.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGarcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez, et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017;19(6):1189\u0026ndash;1201.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShi D, Wu X, Jian Y, Wang J, Huang C, Mo S, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 2022;13(1):5644.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePisanti S, Picardi P, Ciaglia E, D'Alessandro A, Bifulco M. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res. 2014;88:84\u0026ndash;98.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBuhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40(9\u0026ndash;10):575\u0026ndash;584.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGiannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016;17(4):1206.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHalazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319(5868):1352\u0026ndash;1355.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAhmadi M, Amiri S, Pecic S, Machaj F, Rosik J, Łos MJ, et al. Pleiotropic effects of statins: A focus on cancer. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165968.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDemierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5(12):930\u0026ndash;942.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWeissenrieder JS, Reilly JE, Neighbors JD, Hohl RJ. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models. Prostate. 2019;79(1):21\u0026ndash;30.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChang WC, Cheng WC, Cheng BH, Chen L, Ju LJ, Ou YJ, et al. Mitochondrial Acetyl-CoA Synthetase 3 is Biosignature of Gastric Cancer Progression. Cancer Med. 2018;7(4):1240\u0026ndash;1252.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSwamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV, et al Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006;66(14):7370\u0026ndash;7377.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTeraoka N, Mutoh M, Takasu S, Ueno T, Yamamoto M, Sugimura T, et al. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res (Phila). 2011;4(3):445\u0026ndash;453.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"oncogene","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"onc","sideBox":"Learn more about [Oncogene](http://www.nature.com/onc/)","snPcode":"41388","submissionUrl":"https://mts-onc.nature.com/cgi-bin/main.plex","title":"Oncogene","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Colorectal cancer, Tumor cell-intrinsic interferon response, Mevalonate kinase, STAT1 phosphorylation","lastPublishedDoi":"10.21203/rs.3.rs-4819905/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4819905/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eInadequate tumor cell-intrinsic interferon response leads to limited efficacy of immune checkpoint blockade (ICB) therapy, such as anti-PD-1. Cholesterol metabolism can sharply regulate anti-tumor immune response. However, the mechanism of cholesterol synthesis affects the tumor cell-intrinsic interferon response in microsatellite instability (MSI) colorectal cancer (CRC) remains unclear.\u003c/p\u003e\u003ch2\u003eMethod\u003c/h2\u003e \u003cp\u003eSmall interfering RNA(siRNA) libraries and GSEA enrichment analysis are employed to screen out the key molecular which affects the tumor cell-intrinsic interferon response in MSI CRC. Mass cytometry and multiple immunofluorescence (mIF) for detecting changes in tumor micro-environment. The confocal immunofluorescence (IF), truncated protein construction, and co-immunoprecipitation (co-IP) were utilized to investigate the mechanism. The efficacy of immunotherapy were assessed in subcutaneous transplantation tumor models and human peripheral blood mononuclear cells-patient derived xenografts(hPBMC-PDX) models.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eUsing the siRNA library and GSEA analysis, we revealed that mevalonate kinase (MVK) notably impairs the tumor cell-intrinsic interferon response in MSI CRC cells. After MVK gene knockout, the levels of Th1 type chemokines (CXCL9 and CXCL10) and the abundance of CD8\u003csup\u003e+\u003c/sup\u003eT cells were increased in tumor, and tumor growth was significantly slowed in mice with intact immune systems. Mechanistically, MVK interacts with the transcriptional activation domain (TAD) of signal transducer and activator of transcription 1 (STAT1), a key transcription factor in the interferon response. This interaction leads to reduced nuclear translocation of STAT1, ultimately impacting interferon reactivity. In the analysis of the hPBMC-PDX model and the MSI CRC clinical cohort, we observed that a low level of MVK in tumors is associated with a significant efficacy of anti-PD-1 therapy.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eMVK is the crucial medium in the cholesterol metabolism to inhibit the tumor cell-intrinsic interferon response of tumor cells. Moreover, targeting MVK is promising to increase the efficacy of ICB therapy by increasing the interferon response in MSI CRC.\u003c/p\u003e","manuscriptTitle":"Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-08 02:32:51","doi":"10.21203/rs.3.rs-4819905/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2024-09-18T13:54:22+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2024-09-10T09:22:41+00:00","index":2,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2024-09-01T19:08:30+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2024-08-27T03:21:36+00:00","index":2,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2024-08-16T13:58:38+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2024-08-12T14:44:26+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-07-31T10:13:18+00:00","index":"","fulltext":""},{"type":"submitted","content":"Oncogene","date":"2024-07-30T11:36:41+00:00","index":"","fulltext":""},{"type":"checksFailed","content":"","date":"2024-07-29T11:12:36+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-07-29T07:26:19+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"oncogene","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"onc","sideBox":"Learn more about [Oncogene](http://www.nature.com/onc/)","snPcode":"41388","submissionUrl":"https://mts-onc.nature.com/cgi-bin/main.plex","title":"Oncogene","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"38cfedf3-771b-4a91-81f3-7bed08520f82","owner":[],"postedDate":"October 8th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":35938079,"name":"Biological sciences/Cancer/Oncogenes"},{"id":35938080,"name":"Biological sciences/Cancer/Tumour immunology/Immunosurveillance"}],"tags":[],"updatedAt":"2024-12-27T08:06:16+00:00","versionOfRecord":{"articleIdentity":"rs-4819905","link":"https://doi.org/10.1038/s41388-024-03255-2","journal":{"identity":"oncogene","isVorOnly":false,"title":"Oncogene"},"publishedOn":"2024-12-26 05:00:00","publishedOnDateReadable":"December 26th, 2024"},"versionCreatedAt":"2024-10-08 02:32:51","video":"","vorDoi":"10.1038/s41388-024-03255-2","vorDoiUrl":"https://doi.org/10.1038/s41388-024-03255-2","workflowStages":[]},"version":"v1","identity":"rs-4819905","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4819905","identity":"rs-4819905","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}